Roche

FDA Fails to Approve Pfizer's Biosimilar of Roche's Herceptin
FDA Fails to Approve Pfizer's Biosimilar of Roche's Herceptin
CP Wire
Pfizer
FDA
Roche
Herceptin
biosimilars
Flag link:
FDA Fails to Approve Pfizer's Biosimilar of Roche's Herceptin
Pfizer
Herceptin
biosimilars
trastuzumab
Roche
Flag link:
Roche Receives FDA Approval for New Indication for cobas EGFR Mutation Test v2 as a Companion Diagnostic With Tagrisso
Roche Receives FDA Approval for New Indication for cobas EGFR Mutation Test v2 as a Companion Diagnostic With Tagrisso
CP Wire
Roche
cobas EGFR Mutation Test
Tagrisso
non-small cell lung cancer
AstraZeneca
Flag link:
Roche Receives FDA Approval for New Indication for cobas EGFR Mutation Test v2 as a Companion Diagnostic With Tagrisso
Roche
Tagrisso
non-small cell lung cancer
Flag link:
Roche gets double dose of good Hemlibra news with FDA breakthrough, ICER backing
Roche gets double dose of good Hemlibra news with FDA breakthrough, ICER backing
Fierce Pharma
Roche
Hemlibra
hemophilia
FDA
breakthrough status
ICER
Flag link:
We're about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated
We're about to get some key lung cancer data — and it could affect how hundreds of thousands of cancer patients are treated
San Francisco Gate, CA
lung cancer
cancer
Merck
Roche
Bristol-Myers Squibb
AACR
non-small cell lung cancer
Flag link:
Roche halts enrollment in a PhII combo study of Tecentriq and Cotellic in wake of several patient deaths
Roche halts enrollment in a PhII combo study of Tecentriq and Cotellic in wake of several patient deaths
Endpoints
Roche
Tecentriq
clinical trials
colon cancer
Exelixis
Cotellic
Flag link:
Incyte's Horrible News Derails a Promising Class of Cancer Drugs
Incyte's Horrible News Derails a Promising Class of Cancer Drugs
Motley Fool
Incyte
Merck
epacadostat
IDO inhibitors
Roche
NewLink Genetics
Flag link:
Roche Acquires MS Remyelination Program from Versant Ventures
Roche Acquires MS Remyelination Program from Versant Ventures
CP Wire
Roche
MS
multiple sclerosis
remylination
M&A
Versant Ventures
Inception 5
Flag link:
Roche Acquires MS Remyelination Program from Versant Ventures
Roche
Versant Ventures
multiple sclerosis
Flag link:
Under fire for 5 deaths of patients taking Hemlibra, Roche spills details
Under fire for 5 deaths of patients taking Hemlibra, Roche spills details
Fierce Pharma
Hemlibra
Roche
hemophilia
Flag link:
Hemophilia groups warned of 5 deaths among patients taking Roche’s big new blockbuster Hemlibra
Hemophilia groups warned of 5 deaths among patients taking Roche’s big new blockbuster Hemlibra
Endpoints
hemophilia
Roche
Hemlibra
Flag link:
Roche's Avastin could get a boost with Tecentriq's second lung cancer win this week
Roche's Avastin could get a boost with Tecentriq's second lung cancer win this week
Fierce Pharma
Roche
Avastin
Tecentriq
lung cancer
Flag link:
Roche's Tecentriq cocktail notches another lung cancer success
Roche's Tecentriq cocktail notches another lung cancer success
Yahoo/Reuters
Roche
Tecentriq
lung cancer
clinical trials
Flag link:
Amgen and Allergan Hopeful that Herceptin Biosimilar Approval Will Be Around the Corner
Amgen and Allergan Hopeful that Herceptin Biosimilar Approval Will Be Around the Corner
Xtalks
Amgen
Allergan
Herceptin
biosimilars
ABP 980
CHMP
EMA
Roche
Flag link:
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Flag link:
Roche's Tecentriq triumphs in squamous lung cancer. Can it make its mark against Merck?
Roche's Tecentriq triumphs in squamous lung cancer. Can it make its mark against Merck?
Fierce Pharma
Roche
Tecentriq
squamous non-small cell lung cancer
Merck
Keytruda
Flag link:
With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell
With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell
Endpoints
Novartis
Roche
Eylea
Regeneron
Flag link:
AbbVie blockbuster leads 2017 top drug sales; Roche cancer meds follow closely
AbbVie blockbuster leads 2017 top drug sales; Roche cancer meds follow closely
S&P Global
AbbVie
Roche
Humira
Rituxan
Herceptin
Avastin
Flag link:
Beyond Flatiron: The Rising Power Of Oncology Clinical Data Companies
Beyond Flatiron: The Rising Power Of Oncology Clinical Data Companies
Forbes
oncology
Clinical Data
Flatiron Health
Roche
Flag link:

Pages